
AxioMed Spine Stock
AxioMed Spine develops products that restore the spinal function of patients with degenerative spine diseases.
About AxioMed Spine Stock
Funding History
February 2003 | $2.8M |
---|---|
November 2009 | $6.4M |
July 2010 | $9.5M |
October 2010 | $15.0M |
March 2011 | $500K |
May 2012 | $5.0M |
January 2013 | $3.6M |
April 2014 | $1.1M |
Management
President & CEO & Board of Directors
Patrick McBrayer
Vice President for Clinical and Regulatory Affairs
Neal Defibaugh
Co-Founder & CFO
Aditya Humad
Chief Financial Officer
Jerry Baty
COO & Board of Directors
James Kuras
Founder & CEO
Kingsley R. Chin
Press
Other Companies

Addiction Campuses of America
Addiction Campuses of America owns, operates and manages behavioral healthcare campuses across the United States.
Compass Pathways
Compass Pathways will be testing the active ingredient of magic mushrooms, psylocybin, as a treatment for depression.

Contraline
Contraline is developing the first long-lasting, reversible contraceptive for men
EquityZen does not have an affiliation with, formal relationship with, or endorsement from AxioMed Spine or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase